Finding new & better treatments for Type 1 Diabetes
The Type 1 Diabetes UK Immunotherapy Consortium (T1D UK) was set up in 2015 with major funding from Diabetes UK & the JDRF, to promote, develop and support immunotherapy research in T1D.
T1D UK has established a network of 24 Research Sites strategically distributed across the UK to recruit children and adults into clinical trials of new immunotherapy treatments in T1D
There are 2 main cores to T1D UK, a clinical engagement & training core (CET) led by Prof Colin Dayan from Cardiff University and a mechanistic core of 5 specialist Labs located throughout the UK, led by Tim Tree from Kings College, London.
To help get immune therapy into the market as part of the management for type 1 diabetes.
An improved environment for immune therapy trials in the UK: rapid, early and enhanced patient recruitment; enhanced academic engagement with trial design; the provision of a mechanistic core.
The aim of the CET team is to support recruitment into immune therapy trials. The team will co-ordinate and promote trials to Research Sites, engage with teams at the sites and develop and deliver a training programme for research and clinical teams at sites.
The mechanistic core brings together experts in the immunology of T1D from 5 different labs across the UK: Bristol, Cardiff, Oxford, King’s College London, & Queen Mary’s London. These laboratories will provide state of the art immunological assays that will study the impact of immune therapy trials, investigating exactly how different treatments work to control the immune attack that causes type 1 diabetes and working out if it is possible to predict who will benefit from each treatment.
Colin Dayan explains immunotherapy for T1D – here interviewed by Vivienne Parry OBE prior to a plenary lecture at the EASD in Berlin Sept 2018.